
1984
CURE SMA WAS FOUNDED.
We have grown to be the largest network of individuals, families, clinicians, and research scientists working together to advance SMA research, support the SMA community, and educate public and professional communities about SMA.
1995
Discovery of back-up gene as target for therapies.
1999
Identification of SMN1 gene that causes SMA.
2000
First-ever SMA drug development program started.
2001
First drug studied in SMA mice.
2008
First study testing antisense therapy in SMA mice by Ionis.
2009
First ever Orphan Drug Status awarded by the FDA for an SMA therapy.
2010
First study testing gene therapy in SMA mice.
2011
First-ever clinical trial approved for an SMA-specific drug.
2014
First clinical trial testing gene therapy for SMA.
2016
FDA announces approval of Spinraza to treat SMA, making it the first-ever FDA-approved therapy for SMA through Biogen.
2018
HHS Secretary Alex Azar approves adding SMA to the Recommended Uniform Screening Panel (RUSP), a major step towards implementing newborn screening nationwide.
2019
FDA announces approval of Zolgensma for the treatment of children under the age of 2 years with SMA through AveXis, a Novartis Company.
2022
Approximately 97% of all babies born in the U.S. are now screened for SMA.
2022
The Cure SMA Care Center Network comprises 18 hospital sites geographically dispersed throughout the U.S.
cure SMA
2022 AWARENESS MONTH
THE ROAD AHEAD
IMPORTANT MILESTONES